Results 11 to 20 of about 1,411,652 (360)

Hepatitis A, Italy [PDF]

open access: yesEmerging Infectious Diseases, 2005
To the Editor: Hepatitis A virus (HAV) infection rates are very low in industrialized countries. A noticeable fall in the prevalence of HAV antibodies (anti-HAV) has been reported in southern European and Mediterranean countries such as Spain (1) and Greece (2), reflecting improvements in hygiene standards in the last decades.
D'AMELIO, Raffaele   +7 more
openaire   +6 more sources

Hepatitis [PDF]

open access: yesCanadian Journal of Infectious Diseases and Medical Microbiology, 2001
Worldwide, approximately 170 million people are chronically infected with hepatitis C virus (HCV) and another 350 million individuals are chronically infected with hepatitis B virus (HBV) (1,2). Canada is estimated to have 240,000 to 300,000 HCV and 200,000 to 280,000 HBV chronic carriers (3,4).
openaire   +3 more sources

Incidence, prevalence, and clinical course of hepatitis C following liver transplantation [PDF]

open access: yes, 1992
Hepatitis C virus (HCV) is the agent responsible for posttransfusion hepatitis. The incidence, timing, and clinical course of HCV positive hepatitis in liver transplant recipients are unknown.
A.Jake Demetris   +35 more
core   +1 more source

Prevention, testing, and treatment interventions for hepatitis B and C in refugee populations: results of a scoping review

open access: yesBMC Infectious Diseases, 2023
Background and aims Refugees are at higher risk for hepatitis B (HBV) and hepatitis C (HCV), but often face unique healthcare barriers to vaccination, testing, and treatment.
Ankeeta Saseetharran   +5 more
doaj   +1 more source

‘It’s been a long haul, a big haul, but we’ve made it’: hepatitis C virus treatment in post-transplant patients with virus recurrence: An interpretative phenomenological analysis [PDF]

open access: yes, 2018
The lived experience of both interferon-based and new interferon-free treatments in patients with hepatitis C virus remains understudied. To explore their journey through hepatitis C virus treatment, we interviewed seven post-transplant patients with ...
Chouliara, Zoe   +4 more
core   +3 more sources

P-98 BIOCHEMICAL MAKERS AMONG CHRONIC LIVER DISEASE PATIENTS ACCORDING COVID-19 INFECTION: A FOLLOW-UP STUDY

open access: yesAnnals of Hepatology, 2021
Introduction: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly around the world, posing a major threat to human health and the economy.
Lucas Lima da Silva   +10 more
doaj   +1 more source

Experiences of diagnosis, stigma, culpability, and disclosure in male patients with hepatitis C virus: an interpretative phenomenological analysis [PDF]

open access: yes, 2019
The current study aimed to explore the lived experience of patients with hepatitis C virus infection. Semi-structured interviews were conducted with seven male participants living with hepatitis C virus and were analysed using interpretative ...
Adele Dickson   +11 more
core   +3 more sources

Development of Java based graphical user interface for Diagnosis of Hepatitis UsingI Mixture of Expert [PDF]

open access: yes, 2012
Hepatitis is deadly, and the fifth leading cause of death after heart disease, stroke, chest disease and cancer. Worldwide, 1.5 million deaths per year have been estimated. Detection of hepatitis is a big problem for general practitioners.
Ambarish S. Vidyarthi   +2 more
core   +2 more sources

Usefulness of automated assays for detecting hepatitis B and C markers in dried blood spot samples

open access: yesBMC Research Notes, 2019
Objective Dried blood spots (DBSs) can be used as an alternative to serum samples because they are easily collected and can be transported without refrigeration to reference laboratories for diagnosis.
Livia Melo Villar   +6 more
doaj   +1 more source

Hepatitis induced by noni juice from Morinda citrifolia: A rare cause of hepatotoxicity or the tip of the iceberg? [PDF]

open access: yes, 2006
A 24-year-old female patient presented to her community hospital with mild elevations of serum transaminase and bilirubin levels. Because of multiple sclerosis, she was treated with interferon beta-la for 6 weeks.
Diebold, J.   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy